VEGF-A Assay Portfolio Service
Based on profound expertise and first-class techniques, Creative Biolabs is confident in providing an integrated solution for VEGF-A assay services to best suit your program requirements.
Introduction of VEGF-A
VEGF-A is a dimeric glycoprotein belonging to the VEGF family that regulates blood vessels permeability and promotes angiogenesis. The VEGF family contains seven members, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and PlGF. All members share a common structure and contain a core region consisting of eight cysteine residues that form a cysteine knot motif. VEGF receptors occur mainly as the homodimer transmembrane receptor tyrosine kinases, known as VEGFR-1, VEGFR-2 and VEGFR-3, or insoluble forms defined as sVEGFR-1 or sVEGFR-2. VEGF-A glycoprotein typically binds to VEGFR-1 and VEGFR-2 to activate downstream signaling pathways.
Fig.1 Scheme of VEGF and VEGF receptors. (Masłowska, 2021)
VEGF-A as a Therapy Target
VEGF-A, mainly secreted by cancer and stromal cells, regulates vascular permeability, angiogenesis, endothelial cell growth and cell migration. VEGF-A has been found to be abnormally expressed in a variety of tumors, such as colon cancer, lung adenocarcinoma and breast invasive ductal carcinoma. And its overexpression is associated with poor prognosis and metastasis death. In addition, VEGF-A in combination with EGFR also promotes tumor development and metastasis.
To date, several approaches to targeting VEGF have been investigated. For example, Bevacizumab, a humanized VEGF-A-targeted monoclonal antibody has been applied for the treatment of breast and other malignancies.
Fig.2 Types of tumors with VEGF-A abnormal expression. (From the AACR Project GENIE Consortium)
Our VEGF-A Assay Portfolio Services
Creative Biolabs has robustly developed, optimized and validated an integrated tumor marker assay platform. We are committed to providing custom VEGF-A assay portfolio services, from which you can select the best fit for your specific project. We can provide a comprehensive research assay portfolio, covering the initial target validation to the later preclinical analysis to accelerate the research process.
For more details of our VEGF-A assay portfolio services, please don’t hesitate to contact us for more information.
References
-
Masłowska, K.; et al. The Role of VEGF receptors as molecular target in nuclear medicine for cancer diagnosis and combination therapy. Cancers. 2021, 13(5): 1072.
-
Duda, D.G.; et al. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends in molecular medicine. 2007, 13(6): 223-30.
-
The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017, 7(8): 818-831.
For Research Use Only | Not For Clinical Use
Download our brochure